Listed

Oramed Pharmaceuticals Inc.

ORMPNasdaqCIK 1176309HealthcareFiscal year ends Dec 31

Latest reported revenue, Q4 FY2025$0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-26, accession 0001213900-26-034835. Derived: 12-month figure less the 9-month figure.Report this figureThree months to Dec 31, 2025, from the 10-K filed Mar 26, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenuenot reported (Revenue not reported)No year-earlier figure to compare
  • Gross marginnot reported (Gross profit and Revenue not reported)No year-earlier figure to compare
  • Operating marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Net marginnot reported (Revenue not reported)No year-earlier figure to compare
  • Diluted EPS$1.84Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001213900-26-087361.Report this figure+493.5% on a year earlier
  • Free cash flow−$202.0kFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$200.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001213900-26-087361. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001213900-26-087361. Derived: 6-month figure less the 3-month figure.Report this figure+94.3% on a year earlier

Last eight quarters

Full statements
Revenue$0Gross margin not reported
Diluted EPS$1.84, Q2 FY2026
Free cash flow−$202.0k, Q2 FY2026
Oramed Pharmaceuticals Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$knot reported (Revenue not reported)not reported (Revenue not reported)2,000Revenue, Q1 FY2025, three months to 2025-03-31$2.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-19, accession 0001213900-26-059112.Report this figure0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-10, accession 0001213900-26-087361. Derived: 6-month figure less the 3-month figure.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:Revenues. 10-Q filed 2025-11-13, accession 0001213900-25-109980. Derived: 9-month figure less the 6-month figure.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-26, accession 0001213900-26-034835. Derived: 12-month figure less the 9-month figure.Report this figurenot reported (Revenue not reported)not reported (Revenue not reported)
Gross margin%not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)0.7%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $13.0k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-19, accession 0001213900-26-059112.Revenue: $2.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-19, accession 0001213900-26-059112.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Gross profit and Revenue not reported)not reported (Gross profit and Revenue not reported)
Operating margin%not reported (Revenue not reported)not reported (Revenue not reported)(225.0%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$4.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-19, accession 0001213900-26-059112.Revenue: $2.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-19, accession 0001213900-26-059112.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Net margin%not reported (Revenue not reported)not reported (Revenue not reported)(382.1%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$7.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-19, accession 0001213900-26-059112.Revenue: $2.0m. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-19, accession 0001213900-26-059112.Report this figurenot reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue of zero not reported)not reported (Revenue not reported)not reported (Revenue not reported)
Diluted EPS$ per share(0.48)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001213900-25-109980.Report this figurenot reported (Diluted EPS not reported)(0.19)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.19 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-19, accession 0001213900-26-059112.Report this figure0.31Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001213900-26-087361.Report this figure1.13Diluted EPS, Q3 FY2025, three months to 2025-09-30$1.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-13, accession 0001213900-25-109980.Report this figurenot reported (Diluted EPS not reported)0.91Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.91 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-19, accession 0001213900-26-059112.Report this figure1.84Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-10, accession 0001213900-26-087361.Report this figure
Free cash flow$k(7,106)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$7.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001213900-25-109980. Derived: 9-month figure less the 6-month figure.Capital expenditure: $5.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001213900-25-109980. Derived: 9-month figure less the 6-month figure.Report this figure(1,922)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$1.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001213900-26-034835. Derived: 12-month figure less the 9-month figure.Capital expenditure: $11.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001213900-26-034835. Derived: 12-month figure less the 9-month figure.Report this figure(3,522)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-19, accession 0001213900-26-059112.Capital expenditure: $3.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-19, accession 0001213900-26-059112.Report this figure(3,539)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$3.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001213900-26-087361. Derived: 6-month figure less the 3-month figure.Capital expenditure: $4.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001213900-26-087361. Derived: 6-month figure less the 3-month figure.Report this figure(1,625)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$1.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-13, accession 0001213900-25-109980. Derived: 9-month figure less the 6-month figure.Capital expenditure: $0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-13, accession 0001213900-25-109980. Derived: 9-month figure less the 6-month figure.Report this figure(468)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$466.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001213900-26-034835. Derived: 12-month figure less the 9-month figure.Capital expenditure: $2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001213900-26-034835. Derived: 12-month figure less the 9-month figure.Report this figure(2,920)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$2.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-19, accession 0001213900-26-059112.Capital expenditure: $5.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-19, accession 0001213900-26-059112.Report this figure(202)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$200.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-10, accession 0001213900-26-087361. Derived: 6-month figure less the 3-month figure.Capital expenditure: $2.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-10, accession 0001213900-26-087361. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$2.0mGross margin 0.7%
Diluted EPS$1.50, FY2025
Free cash flow−$9.2m, FY2025
Oramed Pharmaceuticals Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-08-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m2.7Revenue, FY2021, twelve months to 2021-08-31$2.7m. XBRL concept us-gaap:Revenues. 10-K filed 2021-11-24, accession 0001213900-21-062009.Report this figure2.7Revenue, FY2022, twelve months to 2022-12-31$2.7m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-06, accession 0001213900-24-020485.Report this figure1.3Revenue, FY2023, twelve months to 2023-12-31$1.3m. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-27, accession 0001013762-25-003450.Report this figurenot reported (Revenue not reported)2.0Revenue, FY2025, twelve months to 2025-12-31$2.0m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-26, accession 0001213900-26-034835.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit and Revenue not reported)0.7%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $13.0k. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-03-26, accession 0001213900-26-034835.Revenue: $2.0m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-26, accession 0001213900-26-034835.Report this figure
Operating margin%(896.2%)Operating margin, FY2021, twelve months to 2021-08-31. operating income / revenueOperating income: −$24.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2021-11-24, accession 0001213900-21-062009.Revenue: $2.7m. XBRL concept us-gaap:Revenues. 10-K filed 2021-11-24, accession 0001213900-21-062009.Report this figure(1502.0%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$40.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-06, accession 0001213900-24-020485.Revenue: $2.7m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-06, accession 0001213900-24-020485.Report this figure(1176.8%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$15.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-27, accession 0001013762-25-003450.Revenue: $1.3m. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-27, accession 0001013762-25-003450.Report this figurenot reported (Revenue not reported)(754.4%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$15.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001213900-26-034835.Revenue: $2.0m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-26, accession 0001213900-26-034835.Report this figure
Net margin%(850.5%)Net margin, FY2021, twelve months to 2021-08-31. net income / revenueNet income: −$23.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2021-11-24, accession 0001213900-21-062009.Revenue: $2.7m. XBRL concept us-gaap:Revenues. 10-K filed 2021-11-24, accession 0001213900-21-062009.Report this figure(1352.6%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$36.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-06, accession 0001213900-24-020485.Revenue: $2.7m. XBRL concept us-gaap:Revenues. 10-K filed 2024-03-06, accession 0001213900-24-020485.Report this figure379.7%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $5.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-27, accession 0001013762-25-003450.Revenue: $1.3m. XBRL concept us-gaap:Revenues. 10-K filed 2025-03-27, accession 0001013762-25-003450.Report this figurenot reported (Revenue not reported)3202.5%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $64.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001213900-26-034835.Revenue: $2.0m. XBRL concept us-gaap:Revenues. 10-K filed 2026-03-26, accession 0001213900-26-034835.Report this figure
Diluted EPS$ per share0.78Diluted EPS, FY2021, twelve months to 2021-08-31$0.78 per share. XBRL concept us-gaap:EarningsPerShareBasicAndDiluted. 10-K filed 2021-11-24, accession 0001213900-21-062009.Report this figure(0.94)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.94 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-06, accession 0001213900-24-020485.Report this figure0.14Diluted EPS, FY2023, twelve months to 2023-12-31$0.14 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-27, accession 0001013762-25-003450.Report this figure(0.48)Diluted EPS, FY2024, twelve months to 2024-12-31−$0.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-26, accession 0001213900-26-034835.Report this figure1.50Diluted EPS, FY2025, twelve months to 2025-12-31$1.50 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-26, accession 0001213900-26-034835.Report this figure
Free cash flow$m(21.6)Free cash flow, FY2021, twelve months to 2021-08-31. operating cash flow − capital expenditureOperating cash flow: −$21.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2023-03-06, accession 0001213900-23-017837.Capital expenditure: $375.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2023-03-06, accession 0001213900-23-017837.Report this figure(28.4)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$27.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-06, accession 0001213900-24-020485.Capital expenditure: $496.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-06, accession 0001213900-24-020485.Report this figure(10.5)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$10.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-27, accession 0001013762-25-003450.Capital expenditure: $254.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-27, accession 0001013762-25-003450.Report this figure(8.4)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$8.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001213900-26-034835.Capital expenditure: $18.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001213900-26-034835.Report this figure(9.2)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$9.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001213900-26-034835.Capital expenditure: $9.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-26, accession 0001213900-26-034835.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Oramed Pharmaceuticals Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
MERCER GLOBAL ADVISORS INC /ADV2026-06-30$18.3m3,810,540Added+1,900,000
Aquamarine Financial (Cayman) Ltd2026-06-30$12.1m2,512,175Added+399,863
Gem Investment Advisors, LLC2026-06-30$9.6m1,998,802Added+358,733
BlackRock, Inc.2026-06-30$7.7m1,608,111Added+1,515,919
Murchinson Ltd.2026-06-30$6.2m1,290,294Reduced−25,000
BML Capital Management, LLC2026-06-30$4.2m866,269Reduced−2,300,962
BOOTHBAY FUND MANAGEMENT, LLC2026-06-30$2.8m578,638Reduced−22,078
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$2.4m500,690Added+476,408
GOLDMAN SACHS GROUP INC2026-06-30$1.2m253,293New+253,293
STATE STREET CORP2026-06-30$1.2m242,100New+242,100

Recent filings

All 809 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Oramed Pharmaceuticals Inc., recent filings
FiledFormWhat it isAccession number
2026-09-1719:37 ET8-K5.07 Shareholder vote results0001213900-26-100929
2026-08-1021:29 ET10-QQuarterly reportPeriod 2026-06-300001213900-26-087361
2026-08-0320:05 ETDEF 14AProxy statementPeriod 2026-09-150001213900-26-084609
2026-07-2216:15 ETSCHEDULE 13D/AOwnership report, active investor, amended0001213900-26-080406
2026-06-3020:19 ET8-K5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits0001213900-26-073709
2026-06-1720:48 ETSCHEDULE 13D/AOwnership report, active investor, amended0001213900-26-069783
2026-05-1921:08 ET10-QQuarterly reportPeriod 2026-03-310001213900-26-059112
2026-05-1417:19 ETSCHEDULE 13DOwnership report, active investor0001213900-26-056837
2026-03-3120:20 ET8-K1.01 Entry into a material agreement; 2.01 Completion of an acquisition or disposition0001213900-26-037474
2026-03-2621:14 ET10-KAnnual reportPeriod 2025-12-310001213900-26-034835

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league

About the filer

CIK
1176309
Tickers
ORMP
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Non-accelerated filer<br>Smaller reporting company
Former names
Integrated Security Technologies, Inc. (to 2006-04-10); IGUANA VENTURES LTD (to 2004-06-10)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:35 ET. Listed shows no prices and gives no investment advice.